NCT00807222 - Effect of Vyvanse on Sleep in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder (ADHD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions

Attention Deficit Hyperactivity DisorderSleep

Interventions

DRUG

lisdexamfetamine dimesylate

Subjects will receive Vyvanse 30, 50, or 70 mg per day or placebo capsules orally for up to (a maximum of) seven (7) weeks.

Trial Locations (1)

Clinical Study Centers, LLC, Little Rock